ClinicalTrials.gg
RecruitingNCT06378021Updated Apr 22, 2024

Role of Calcium Chloride Injection in Alleviating Atrial Fibrillation Post CABG

A Phase 3 interventional study of Calcium Chloride and Sodium Chloride 0.9% Inj in Atrial Fibrillation, sponsored by Helwan University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2024-04-22.

Sponsored by Helwan University · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Atrial Fibrillation with a site in Egypt — 9 open to participants now, 12 under way, 1 of them phase 3. Atrial Fibrillation · Egypt.

Planned enrollment
16th of 21
100 · median 180
Started
2024
with 5 others
Phase 3
4 of 33
1 open now
Primary completion
2025-03
later than 6 of 11 live
Registered
26th of 33
by date
Lead sponsor
3 of 33
Helwan University

Among the 33 studies in Atrial Fibrillation with a site in Egypt, this one is the 16th largest by planned enrollment of the 21 interventional ones that give a count, is one of 6 that started in 2024, is one of 4 in phase 3, reaches primary completion later than 6 of the 11 other live ones, and was the 26th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

9 of the 33 studies in Atrial Fibrillation with a site in Egypt are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Atrial Fibrillation with a site in Egypt, or all of them as a file.
02

Study summary

This study hypothesize that injecting calcium chloride (CaCl2) into the major atrial ganglionated plexus (GPs) during on pump Coronary artery bypass graft (CABG) can reduce the incidence of Post operative Atrial fibrillation in the first 7 days after surgery.The study is designed to be prospective interventional study two armed RCT for on pump CABG patient.

The intervention arm will be injected with Calcium chloride in the four major atrial ganglionic plexus The control arm will be injected with sodium chloride to determine the effect of Calcium chloride on Post CABG Atrial fibrillation

Read the detailed description

This study hypothesize that injecting calcium chloride into the major atrial ganglionic plexus (GPs) during On pump Coronary artery bypass graft (CABG) can reduce the incidence of Post operative Atrial fibrillation by calcium-induced autonomic neurotoxicity, the incidence of Post operative Atrial fibrillation can be reduced by suppressing the function of the major atrial GPs and the surrounding neural network that play an important role in initiating Post operative Atrial fibrillation. The study is designed to be prospective interventional study two armed RCT for on pump CABG patient. The plan of work will include dividing the patients into 2 randomized control groups In the intervention group patients will be injected with 5% Calcium chloride in the 4 Major atrial ganglionic plexus The other arm will be Coronary artery bypass graft patients who will be injected with sodium chloride 0.9% to compare the two groups to evaluate to evaluate the effect of Calcium chloride in post CABG atrial fibrillation between the 2 arms of the study.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Atrial fibrillation
  • Calcium chloride
  • On pump Coronary artery bypass graft
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients more than 18 years old 2 ) patients undergoing On pump CABG

Exclusion criteria

Exclusion Criteria:

  1. patients >75 years of age
  2. Patients with Pre operative Atrial fibrillation
  3. Patients with Significant valvular disease
  1. \<30% 6. Combined surgery of any kind 7. Congenital heart disease 8. Abnormal severe liver or kidney dysfunction. 9. Patients undergoing Off-pump CABG 10. Poorly controlled hyperthyroidism 11. Refusal to enrollment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Calcium chloride injection in ganglionated plexis for Atrial Fibrillation alleviation post CABG

    The Patients in the intervention arm will be injected with Calcium chloride in the 4 major atrial ganglionated plexis after the by pass is completed.

    Drug: Calcium Chloride

  • Placebo comparator
    patients who will receive their regular standard of care without calcium chloride injection

    A group of patients who will undergo Coronary artery bypass graft surgery will be injected with normal saline in the ganglionic Plexus during Coronary artery bypass graft to act as a comparator to determine if calcium chloride injection alleviate Atrial fibrillation post surgery

    Drug: Sodium Chloride 0.9% Inj

Interventions

  • 5 % calcium chloride injection in cardiac ganglionic Plexus during On pump Coronary artery bypass graft

    Also known as: 10% ampoules calcium chloride

  • DrugSodium Chloride 0.9% Inj

    0.9% sodium chloride injection during on pump during Coronary artery bypass graft

    Also known as: Normal saline

06

What researchers measure

Primary outcomes

  1. Change in number of patients who developed Atrial fibrillation

    Compare if calcium chloride injection decrease the percentage of patients who developed Atrial fibrillation in intervention group with those in placebo group

    Time frame: Up to one week from the time of surgery determined by serial ECGs per day

Secondary outcomes

  1. Change in length of hospital stay

    investigate if calcium chloride will decrease duration of hospital stay compared with those in the placebo group who are injected with normal saline

    Time frame: Up to the time of patient discharge from the hospital (from the time of post Coronary artery bypass graft surgery)

07

Study locations

1 of 1 sites recruiting
  • Ain shams university
    Cairo, Abassia Cairo 02, Egypt
    Recruiting
    • Mohamed A Gamal, Ass prof · Contact010080827060
    • Abdelhameed I Ebid, Prof · Principal investigator
08

References and documents

Publications

  • Wang H, Zhang Y, Xin F, Jiang H, Tao D, Jin Y, He Y, Wang Q, Po SS. Calcium-Induced Autonomic Denervation in Patients With Post-Operative Atrial Fibrillation. J Am Coll Cardiol. 2021 Jan 5;77(1):57-67. doi: 10.1016/j.jacc.2020.10.049. PubMed 33413942 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2025, 12 months after the start.

Of 62 non-industry phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 73. This study's planned 12 months is below that.

Counting every sponsor, half of 83 studies reached it within 42 months; a quarter within 32 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2024
First posted
Apr 22, 2024
StartActual
Mar 14, 2024
Primary completionEst.
Mar 2025
CompletionEst.
Apr 2025
Last update
Apr 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06378021
Lead sponsor
Helwan University
Responsible party
Nadine Osama Elgarhi (Doctor of pharmacy, Helwan University) — Principal investigator
First posted
Apr 22, 2024
Start date
Mar 14, 2024
Primary completion
Mar 2025 (estimated)
Completion
Apr 2025 (estimated)
Last update
Apr 22, 2024

Study contacts

Nadine O Elgarhi, pharmacist
Contact
nadinesadek2013@hotmail.com
01144249948 ext. 02
Ahmed A Foad, Assoc prof
Contact
01114567874 ext. 02
Abdelhameed I Ebid
principal investigator · Prof

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Calcium Chloride

Start the discussion